Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. (NASDAQ: KMDA) reported its full-year 2022 financial results, achieving total revenues of $129.3 million and EBITDA of $17.8 million, a 25% increase year-over-year. The company has transitioned from reliance on GLASSIA® sales to a diversified portfolio with six FDA-approved products. Operating cash flow reached $28.6 million, improving the cash position to $34.3 million. For 2023, Kamada projects revenues between $138 million and $146 million and EBITDA of $22 million to $26 million, signaling continued growth driven by strong product demand and expansion in various markets.

Kamada Ltd. reported fiscal year 2022 revenues of $129.3 million, a 25% increase from 2021, with EBITDA of $17.8 million, reflecting a 3x increase year-over-year. The fourth quarter alone saw revenues of $45.4 million, up 44% compared to the previous year. The company forecasts fiscal year 2023 revenues between $138 million and $146 million, representing anticipated growth. Key drivers include sales from CYTOGAM®, KEDRAB®, and GLASSIA® royalties. Kamada also achieved a record operating cash flow of $28.6 million in 2022, enhancing its cash position to $34.3 million.

Kamada Ltd. (NASDAQ: KMDA), a biopharmaceutical company focusing on rare diseases, will announce its financial results for Q4 and the full year ending December 31, 2022, on March 15, 2023, before U.S. market open. A conference call will be held the same day at 8:30 AM ET to discuss the results. Investors can participate by calling specific numbers or via a live webcast. Kamada's portfolio includes six FDA-approved plasma-derived products and a notable investigational product for AAT deficiency currently in a pivotal Phase 3 trial. The company aims to drive growth through its commercial strategies and R&D advancements.

Kamada Ltd. (NASDAQ: KMDA) announced it has submitted an application to the FDA to manufacture CYTOGAM® at its Israeli facility, expecting approval by mid-2023. This marks the completion of the technology transfer from CSL Behring. CYTOGAM is crucial for preventing cytomegalovirus disease post-transplantation and has the highest sales among Kamada's acquired IgG products, with gross margins exceeding 50%. The company plans to initiate commercial manufacturing in the second half of 2023, leveraging its operational capabilities for increased efficiency.

Kamada Ltd. (NASDAQ: KMDA) announced that its CFO, Chaime Orlev, will leave the company effective March 15, 2023, to pursue new opportunities. Orlev has been with Kamada since 2017 and played a crucial role in its transformation into a diversified biopharmaceutical company. As part of the transition, he will support the onboarding of his successor. Kamada specializes in specialty plasma-derived therapeutics and has a robust portfolio of FDA-approved products. It operates in over 30 countries and continues to advance its development pipeline, including ongoing clinical trials.

Kamada Ltd. (NASDAQ: KMDA) reported third-quarter 2022 revenues of $32.2 million, a 40% increase from the previous year, driven by the integration of its new FDA-approved IgG portfolio. Adjusted EBITDA reached $6.0 million, equating to a 19% margin. The company’s operating cash flow amounted to $5.5 million, elevating its cash position to $31.3 million as of September 30, 2022. Kamada reiterates its fiscal year 2022 revenue guidance of $125 million to $135 million, projecting a 20% to 30% increase over 2021.